

S4 Table. Post-consolidation: high risk

Drug	Dose	Days
Interim maintenance (11 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 15, 29
Methotrexate (IV)	5 g/m ²	1, 15, 29
HD-Cytarabine (IV)	3 g/m ² (q 12 hours)	43, 44
l-Asparaginase (IM)	6,000 u/m ² (max, 10,000 u)	44
6-Mercaptopurine (PO)	60 mg/m ²	64 - 77
Methotrexate (IT)	By age ^{a)}	1, 15, 29, 43
Delayed intensification (8 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2mg)	1, 15, 29, 43
Daunorubicin (IV)	30 mg/m ²	1, 15, 29, 43
Cytarabine (IV)	100 mg/m ²	1-5, 29-33
Cyclophosphamide (IV)	1,200 mg/m ²	15, 43
l-Asparaginase (IM)	6,000 u/m ² (max, 10,000 u)	16, 18, 20, 44, 46, 48
Prednisolone (PO)	45 mg/m ² (max. 60 mg)	1-5, 15-19, 29-33, 43-47
Methotrexate (IT)	By age ^{a)}	1, 29
Interim maintenance-II (6 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 22
Methotrexate (IV)	500 mg/m ²	1, 22
Prednisolone (PO)	45 mg/m ² (max. 60 mg)	1-5, 22-26
6-Mercaptopurine (PO)	60 mg/m ²	1-42
Methotrexate (IT)	By age ^{a)}	1, 22
Delayed intensification-II (7 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 15
Daunorubicin (IV)	30 mg/m ²	1, 15
Cytarabine (IV)	100 mg/m ²	1-5
Cyclophosphamide (IV)	1,200 mg/m ²	15
l-Asparaginase (IM)	6,000 u/m ² (max, 10,000 u)	16, 18, 20, 30
Prednisolone (PO)	45 mg/m ² (max. 60 mg)	1-5, 15-19
HD-Cytarabine (IV)	3 g/m ² (q 12 hours)	29, 30
Methotrexate (IT)	By age ^{a)}	1, 29

Schema: IM#1 (HD-MTX x3, HD-Ara x1) → DI#1 → IM#2 (ID-MTX x2) → DI#2 → Maint. DI, delayed intensification; HD-Ara, high dose cytarabine; HD-MTX, high dose methotrexate; IM,

intramuscular; IT, intrathecal; IV, intravenous; Maint., maintenance; PO, per os. ^{a)}Age-adjusted doses of intrathecal methotrexate: 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years).